In the randomized KEYLYNK-010 study presented by Dr. Evan Yu, #Pembrolizumab + #olaparib (P+O) failed to improve rPFS or OS in heavily pretreated #mCRPC patients compared to next generation hormonal agent.
KEYLYNK-010 trial
Oncologyme
/ Mar 26, 2023
.png)